Hologic HOLX is set to release third-quarter fiscal 2025 results on July 30, after the closing bell. The Zacks Consensus Estimate for third-quarter earnings per share (EPS) suggests a 0.9% decrease ...

I am initiating a Buy rating on Hologic, Inc. with a fair value of $81, as current risks are priced in. Hologic's strong diagnostic portfolio, recurring consumables revenue, and expanding assay menu ...

Hologic (HOLX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Hologic (HOLX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

The valuation also compares favorably to peers QIAGEN QGEN and Abbott ABT, which have a P/S of 3.30X and 2.50X, respectively. Still, the stock trades at a premium to the broader Medical sector’s ...

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - imaging, diagnostics ...

Marlborough, Massachusetts-based Hologic, Inc. (HOLX) develops, manufactures, and supplies diagnostic products, imaging systems, and surgical products for women's health through early detection and ...

Private equity firms TPG and Blackstone (NYSE:BX) recently bid to acquire Hologic Inc. (NASDAQ:HOLX), valuing the U.S. medical technology company at over $16 billion. Hologic is an American medical ...

Shares of Hologic Inc. HOLX dropped more than 3% in the aftermarket Monday after the medical technology company topped Wall Street estimates for its fiscal third quarter and tweaked its guidance for ...

Hologic Inc (NASDAQ:HOLX) posted Q3 adjusted EPS of $0.93, down from $0.95 a year ago and beating the consensus of $0.88. Revenue of $984.4 million decreased 1.8% Y/Y (down 1.6% on constant currency), ...